NIH × Hodgkin Disease × Cyclophosphamide × Clear all
NCT02208037 2019-01-23

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
279 enrolled 28 charts
NCT00295997 2014-01-06

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

National Cancer Institute (NCI)

Phase NA Unknown
35 enrolled
NCT00004061 2013-06-26

Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
111 enrolled
NCT00004132 2013-06-26

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
NCT00080925 2012-03-08

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
20 enrolled
NCT00740467 2010-01-28

Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders

National Cancer Institute (NCI)

Phase 2 Unknown
50 enrolled